Clinical Trial Detail

NCT ID NCT03900949
Title Testing the Combination of Standard Induction Therapy With Gemtuzumab Ozogamicin and Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors OHSU Knight Cancer Institute
Indications

acute myeloid leukemia

Therapies

Midostaurin

Cytarabine

Cytarabine + Gemtuzumab ozogamicin

Cytarabine + Daunorubicin + Gemtuzumab ozogamicin

Age Groups: adult senior

Additional content available in CKB BOOST